Covid-19 roundup: J&J of­fers new da­ta to sup­port boost­ers — but some ex­perts are not im­pressed; Thai­land uni­ver­si­ty's ro­bot­ic arm max­i­mizes vac­cine vials

Amidst all the boost­er shot talk with Pfiz­er and Mod­er­na, J&J on Wednes­day of­fered new da­ta that may lead to its own sin­gle-shot boost­er.

New in­ter­im da­ta from Phase I/IIa tri­als showed that J&J’s boost­er gen­er­at­ed a lev­el of spike-bind­ing an­ti­bod­ies that was 9-fold high­er than 28 days af­ter the first sin­gle-dose shot.

“We have es­tab­lished that a sin­gle shot of our COVID-19 vac­cine gen­er­ates strong and ro­bust im­mune re­spons­es that are durable and per­sis­tent through eight months. With these new da­ta, we al­so see that a boost­er dose of the John­son & John­son COVID-19 vac­cine fur­ther in­creas­es an­ti­body re­spons­es among study par­tic­i­pants who had pre­vi­ous­ly re­ceived our vac­cine,” glob­al head of R&D Math­ai Mam­men said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER